Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Investec sees flat H1 profits amid mixed regional performance

(Sharecast News) - Banking and wealth management firm Investec said on Friday that it expects interim results to be broadly in line with the prior period, supported by a solid performance across its core banking and wealth operations despite a volatile macro backdrop. For the six months ended 30 September, adjusted earnings per share were expected to be between 38.7p and 41.5p, compared with 39.5p a year earlier, while adjusted operating profits before tax were seen between £451.0m and £481.8m, versus £474.7m previously. Pre-provision adjusted operating profits were seen at £509.4m to £540.3m, slightly behind last year's £541.6m figure.

In Southern Africa, specialist banking profit was expected to be up to 7% ahead in SAR terms, though overall regional profit may be flat due to weaker performance in group investments. The UK business, including Investec's stake in Rathbones, was expected to deliver operating profits between 1% behind and 6% ahead of the prior year.

Core loans rose 4.7% annualised to £33.0bn, while customer deposits fell 1.9% to £40.8bn, reflecting a strategic shift in liability mix. Funds under management in Southern Africa climbed 7.8% to £25.2bn.

The FTSE 250-listed firm added that it had repurchased £46m of its £100m buyback programme and maintained strong capital levels, with CET1 ratios of 15.3% in South Africa and 12.2% in the UK, and also reaffirmed its medium-term targets, with group return on equity expected to between 13% and 14%, and return on tangible equity seen coming in somewhere between 15% and 16%.

As of 0810 BST, Investec shares were down 0.81% at 580.24p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.